# TOPACIO (NCT02657889)

> Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02657889
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Tesaro, Inc.
- Conditions: Neoplasms; Triple Negative Breast Cancer; Ovarian Cancer; Breast Cancer; Metastatic Breast Cancer; Advanced Breast Cancer; Stage IV Breast Cancer; Fallopian Tube Cancer; Peritoneal Cancer
- Interventions: niraparib; pembrolizumab
- Enrollment: 122
- Primary outcome: Phase 1: Number of Participants Reporting Dose-Limiting Toxicities (DLTs)
- Primary outcome: Phase 2: Objective Response Rate (ORR) as Measured by Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 1
- Podcasts: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=topacio-nct02657889